[go: up one dir, main page]

EE200300074A - BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon - Google Patents

BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon

Info

Publication number
EE200300074A
EE200300074A EEP200300074A EEP200300074A EE200300074A EE 200300074 A EE200300074 A EE 200300074A EE P200300074 A EEP200300074 A EE P200300074A EE P200300074 A EEP200300074 A EE P200300074A EE 200300074 A EE200300074 A EE 200300074A
Authority
EE
Estonia
Prior art keywords
bcl
pharmaceutical composition
antisense oligonucleotide
antisense
oligonucleotide
Prior art date
Application number
EEP200300074A
Other languages
English (en)
Inventor
P. Warrel Raymond Jr.
E. Klem Robert
Fingert Howard
Original Assignee
Genta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Incorporated filed Critical Genta Incorporated
Publication of EE200300074A publication Critical patent/EE200300074A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300074A 2000-08-25 2001-08-23 BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon EE200300074A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US23700900P 2000-09-29 2000-09-29
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2001/026414 WO2002017852A2 (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (1)

Publication Number Publication Date
EE200300074A true EE200300074A (et) 2004-12-15

Family

ID=27397795

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300074A EE200300074A (et) 2000-08-25 2001-08-23 BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon

Country Status (32)

Country Link
US (2) US7795232B1 (et)
EP (2) EP1313514B1 (et)
JP (1) JP2004507480A (et)
KR (1) KR20030034153A (et)
CN (1) CN1471408A (et)
AP (1) AP2003002761A0 (et)
AT (1) ATE432717T1 (et)
AU (2) AU8837301A (et)
BG (1) BG107641A (et)
BR (1) BR0113447A (et)
CA (1) CA2419480A1 (et)
CY (1) CY1109340T1 (et)
CZ (1) CZ301582B6 (et)
DE (1) DE60138892D1 (et)
DK (1) DK1313514T3 (et)
DZ (1) DZ3471A1 (et)
EA (1) EA005424B1 (et)
EE (1) EE200300074A (et)
ES (1) ES2327904T3 (et)
GE (1) GEP20063934B (et)
HR (1) HRP20030102A2 (et)
HU (1) HUP0303125A2 (et)
IL (1) IL154409A0 (et)
MX (1) MXPA03001575A (et)
NO (1) NO20030858L (et)
OA (1) OA12586A (et)
PL (1) PL363050A1 (et)
PT (1) PT1313514E (et)
SK (1) SK3652003A3 (et)
UA (1) UA77945C2 (et)
WO (1) WO2002017852A2 (et)
YU (1) YU13603A (et)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP2261368A1 (en) 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003295561A1 (en) * 2002-11-14 2004-06-15 Genta Salus Llc Inhibitory oliogonucleotides targeted to bcl-2
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1597391B1 (en) 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP1640452A4 (en) 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
WO2005039382A2 (en) 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
ATE498022T1 (de) 2003-12-23 2011-02-15 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
CA2577938C (en) 2004-08-26 2013-04-16 Himanshu Brahmbhatt Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
AU2005304878B2 (en) 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (ja) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
ES2419106T3 (es) 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Formulación de liposomas anfóteros
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of bcl-2
AU2009316773A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
MX2012001244A (es) 2009-07-30 2012-03-26 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta.
JP5963680B2 (ja) * 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
PL3319995T3 (pl) * 2015-07-07 2019-09-30 F. Hoffmann-La Roche Ag Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
JP7707184B2 (ja) * 2020-03-18 2025-07-14 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP0633934A1 (en) 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modified cells and method of treatment
ATE200427T1 (de) 1992-10-21 2001-04-15 Univ Temple Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
OA12586A (en) 2006-06-07
BG107641A (bg) 2004-01-30
HUP0303125A2 (hu) 2003-12-29
CA2419480A1 (en) 2002-03-07
DZ3471A1 (fr) 2002-03-07
PL363050A1 (en) 2004-11-15
NO20030858D0 (no) 2003-02-24
EP1313514A4 (en) 2005-07-13
EP1313514B1 (en) 2009-06-03
AU8837301A (en) 2002-03-13
WO2002017852A2 (en) 2002-03-07
IL154409A0 (en) 2003-09-17
EP1313514A2 (en) 2003-05-28
AU2001288373B2 (en) 2006-05-11
ATE432717T1 (de) 2009-06-15
CN1471408A (zh) 2004-01-28
SK3652003A3 (en) 2003-08-05
JP2004507480A (ja) 2004-03-11
EA005424B1 (ru) 2005-02-24
DK1313514T3 (da) 2009-10-12
US20100216867A1 (en) 2010-08-26
ES2327904T3 (es) 2009-11-05
EP2135623A1 (en) 2009-12-23
BR0113447A (pt) 2003-07-08
MXPA03001575A (es) 2004-11-01
KR20030034153A (ko) 2003-05-01
NO20030858L (no) 2003-04-24
AP2003002761A0 (en) 2003-06-30
WO2002017852A3 (en) 2003-04-03
PT1313514E (pt) 2009-09-01
US7795232B1 (en) 2010-09-14
CY1109340T1 (el) 2014-07-02
CZ301582B6 (cs) 2010-04-21
EA200300294A1 (ru) 2003-08-28
HK1056505A1 (en) 2004-02-20
CZ2003848A3 (cs) 2003-11-12
HRP20030102A2 (en) 2005-04-30
YU13603A (sh) 2006-05-25
GEP20063934B (en) 2006-10-10
DE60138892D1 (de) 2009-07-16
UA77945C2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
EE200300074A (et) BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
HUP0301452A3 (en) Pharmaceutical composition containing photochemotherapeutic agent and mucoadhesive agent and its use
HUP0302550A3 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines and pharmaceutical compositions containing them
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
EE200200535A (et) Konjugeeritud östrogeenide ja medroksüprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimisühik ja pakend
NO20025450L (no) Ny farmasöytisk sammensetning
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
HUP0301482A3 (en) Quinolinnyl and benzothiazolyl ppar-gamma modulators pharmaceutical compositions containing them and their use
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
EE200200393A (et) Glüburiidi ravimkoostis
HUP0300909A3 (en) 2-guanidino-4-arylchinazolines as nhe-3 inhibitors, pharmaceutical compositions containing them and their use
HUP0302455A3 (en) Combination pharmaceutical compositions containing amplodipine and benazepril and their use
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
HUP0301713A3 (en) Pharmaceutical compositions containing propenone derivatives and their use
EP1299337A4 (en) HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
HE1A Change of address